Drugs / human cord blood-derived mononuclear cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05999656 | May 2023 → May 2024 | — | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human cord blood-derived mononuclear cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05999656 ↗ |
| Known as | HCB-MNCs | “human cord blood-derived mononuclear cells (HCB-MNCs)” NCT05999656 ↗ |
| Route | Intramuscular | “HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet” NCT05999656 ↗ |
| Route | Subcutaneous | “HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet” NCT05999656 ↗ |